I nɔ kin izi fɔ tɔk bɔt di fred ɛn wɔri we pɔsin kin gɛt we dɛn no se i gɛt bɔdi kansa. Bɔt we di sayɛns bɔt mɛrɛsin dɔn go bifo, bɔku advans tritmɛnt dɛn de naw fɔ mɛn ɛn kɔntrol kansa. Orserdu na wan pan dɛn nyu op dɛn de, we na spɛshal mɛrɛsin we de ambɔg di kansa sɛl dɛn. Lɛ wi tɔk bɔt dis simpul ɛn klia wan tide.
Us kayn mɛrɛsin na Orserdu?
Fɔ tɔk am simpul wan, Orserdu na
ɔmon tritmɛnt we dɛn kin yuz fɔ mɛn pipul dɛn . Naw yu go de wɔnda se, "Wetin na dat?" Insay di
kemotɛrapi tritmɛnt we wi kin yɛri bɔt, na lɛk ɔl di sɛl dɛn we de sheb kwik kwik wan kin afɛkt. Dis min se nɔto jɔs di kansa sɛl dɛn nɔmɔ, bɔt di wɛlbɔdi sɛl dɛn na wi bɔdi kin pwɛl. Bɔt pan targeted therapy, sɔmtin difrɛn kin apin. Dɛn mɛrɛsin ya rili smat, dɛn kin no sɔntin lɛk wan patikyula prɔtin ɔ jin we de ɛp di kansa sɛl dɛn fɔ gro, ɛn dɛn kin tɔch am. Orserdu na speshali apruv fɔ:
- Estrogen Risεptor -positiv (ER-positiv ) εn
- Human epidamal growth fכktכr rεsεptכr 2-nεgεtiv ( HER2-nεgεtiv ), .
- Fɔ brɔst kansa we dɔn skata to ɔda pat dɛn na di bɔdi (advans ɔ metastatic).
pan tap dat, dεn kin gi dis tritmεnt to pipul dεm we gεt
mכtεshכn (jin chenj) na wan jin we dεn kכl ESR1 . Dɛn kin gi dis mɛrɛsin fɔ pipul dɛm wae dɔn gɛt ɔda ɔmon tritmɛnt dɛm ɛn wae dɛn kansa nɔr dɔn ansa dɛn fayn ɛn dɔn kam bak. I kin kam lɛk pil we dɛn kin tek wan tɛm insay di de.
Aw dis mɛrɛsin de wok na di bɔdi?
Fɔ ɔndastand dis, lɛ wi fɔs tek wan luk pan ER-positiv kansa. Dis kayn kansa sɛl tan lɛk smɔl plant. Da plant de nid wan ɔmon we dɛn kɔl ‘ɛstrojen’ lɛk wata fɔ mek i gro. So, bɔku pan di ɔmon tritmɛnt dɛn kin stɔp dis ɛstrojen fɔ go na di kansa sɛl. Bɔt sɔntɛnde, we yu tek dis tritmɛnt fɔ sɔm tɛm,
wan jin we dɛn kɔl ESR1 na di kansa sɛl dɛn kin chenj . Bikɔs ɔf dis chenj, di ɔmon drɔgs we dɛn bin de gi am trade nɔ kin ebul fɔ kɔntrol di kansa igen. Di kansa kin bigin fɔ gro bak.
Imajin se wan kansa sɛl gɛt spɛshal riseptɔ we di ɔmon we dɛn kɔl ɛstrojen kin kech. Orserdu de wok bay we i de target di kansa sεl dεm we bin de rεsist to dכg bifo bikoz fכ da jεnεtik mכtεshכn de.Di aidia na fɔ rich na da domɔt de na di pit, fɔ rich de bifo ɛstrojen, ɛn lɔk da domɔt de. Dɔn di ɛstrojen ɔmon nɔ gɛt chans fɔ mek di kansa sɛl gro.
Aw a go no if Orserdu rayt fɔ mi?
Dis na kwɛstyɔn we rili impɔtant. Orserdu nɔto mɛrɛsin we dɛn kin gi ɔl di wan dɛn we gɛt bɔdi kansa. Yu dɔktɔ we de mɛn kansa na di bɛst pɔsin fɔ disayd fɔ du dis. Jɛnɛral wan, dɛn kin tink bɔt dis tritmɛnt fɔ di wan dɛn we mit dɛn krayteria ya:
Situeshɔn dɛm wae dɛn kin tink bɔt yu fɔ Orserdu tritmɛnt
| Di kɔndishɔn we di pɔsin we sik gɛt | Yu fɔ bi uman we dɔn pas 40 ia ɔ big man. |
| Di kayn kansa we yu gɛt | Di kansa fɔ bi ER-positiv ɛn HER2-negativ. |
| Di we aw kansa de skata | Di kansa fɔ dɔn go bifo ɔ i fɔ dɔn spre to ɔda pat dɛn na di bɔdi (mɛtastatik). |
| Tɛst dɛn we dɛn kin du fɔ tɛst dɛn jɛnɛtiks | Spɛshal tɛst dɛn fɔ dɔn kɔnfyus se yu kansa gɛt ESR1 jin muteshɔn . |
| Bifo dɛn trit am | Yu fɔ dɔn gɛt at le wan kayn ɔmon tritmɛnt bifo ɛn di kansa fɔ dɔn kam bak di tɛm ɔ afta da tritmɛnt de. |
Yu dɔktɔ go disayd fɔ no if dis mɛrɛsin fayn fɔ yu afta i dɔn du di jenɛtik tɛst dɛn we yu nid ɛn luk yu kɔmplit mɛdikal rɛkɔd.
Di sayd effekt dɛm fɔ Orserdu ɛn aw fɔ dil wit dɛm?
Lɛk ɛni mɛrɛsin, Orserdu kin mek sɔm sayd ɛfɛkt dɛn. Bɔt bɔku pan dɛn tin ya nɔ kin izi fɔ du ɛn dɛn kin ebul fɔ kɔntrol dɛn.
De tin wae impɔtant pas ɔl na fɔ tɛl yu dɔktɔ wantɛm wantɛm bɔt ɛni nyu sayn wae yu gɛt.| Kɔmɔn sayd ɛfɛkt dɛn | Tips fɔ manej |
|---|
| Mɔsul ɛn jɔyn pen, ed pen | Tɔk to yu dɔktɔ bɔt fɔ gɛt di rayt mɛrɛsin fɔ mek yu nɔ fil pen fɔ dis. |
| Nɔs, vɔmit, bɛlɛ at, dayarɛa, ɔ kɔnstipɛshɔn | - It smɔl smɔl it dɛn bɔku tɛm insay di de. - Nɔ it tin dɛn we gɛt ɔyl ɛn fat. - Ad mɔ vɛjitebul ɛn frut dɛn. |
| Anorexia we pɔsin kin gɛt | - It smɔl it ɔl di de we yu fil angri. - Tray fɔ it shek we gɛt fayn fayn tin dɛn ɔ fɔ it tin dɛn we gɛt likwid. |
| Hot flush dɛn | - Wear layt, lɔs klos. - Ridyus strɛs. We yu de du ɛksasaiz fɔ blo dip dip wan kin ɛp. |
| We pɔsin taya | Gɛt bɔku rɛst as yu ebul. We yu plan fɔ du di tin dɛn we yu go du fɔ yu de, dat go ɛp yu fɔ kip yu trɛnk. |
Apat frɔm dat, Orserdu kin mek di blɔd kɔlɔstrel ɛn triglisrayd lɛvɛl go ɔp. I kin afɛkt bak di we aw di liva ɛn di kidni de wok. So, yu dɔktɔ go de wach dɛn tin ya wit blɔd tɛst ɔltɛm.
Aw Orserdu kin intarakt wit ɔda mɛrɛsin ɛn it dɛn?
Dis rili impɔtant. Bifo yu bigin fɔ tek Orserdu, yu fɔ tɛl yu ɔnkɔlɔjis bɔt
ɔl di mɛrɛsin dɛn we yu de tek naw (inklud di mɛrɛsin fɔ ɔda sik dɛn, vaytamɛn, ɛn ɛbul prɔdak dɛm) . Dis na bikɔs sɔm mɛrɛsin ɛn it kin afɛkt di we aw Orserdu de wok na di bɔdi.
- CYP3A inhibitors: Dis klas fכ drog כ it kin delay fכ pul Orserdu kכmכt na di bכdi. Dis kin mek di drog na di bɔdi go ɔp, .Di sayd ɛfɛkt dɛn kin bɔku. Ɛgzampul dɛn: Sɔm antibayɔtik, antifɔngal, ɛn frut dɛn lɛk grep ɛn pomelo.
- CYP3A inducers: Dis klas fכ dכg de mek dεn kכl Orserdu kכmכt na di bכdi kwik kwik wan. Dis kin mek di mɛrɛsin nɔ wok fayn . Ɛgzampul: Sɔm mɛrɛsin fɔ ɛpilepshi, sɔm antibayɔtik.
So,
mek shɔ se yu go to yu dɔktɔ bifo yu bigin ɔ stɔp ɛni nyu mɛrɛsin we yu de tek Orserdu. Mɛsej we dɛn kin kɛr go na os
- Orserdu (elacestrant) na wan nyu tכgεt כmon tεrapi fכ di tritmεnt fכ advans, ER-positiv, HER2-nεgεtiv brεst kεnsar.
- Dis tritmɛnt na fɔ di wan dɛn we gɛt ESR1 jin muteshɔn ɛn we nɔ de ansa ɔda ɔmon tritmɛnt dɛn .
- Risach dɔn sho se dis drɔg de ɛkstɛnd di prɔgrɛs-fri sɔvayv (di tɛm we dɛn kin kɔntrol di kansa we nɔ go wɔs).
- Sɔm sayd ɛfɛkt lɛk nɔs, pen na yu jɔyn, ɛn taya kin apin, bɔt dɛn kin ebul fɔ kɔntrol dɛn. Ripɔt ɛni sayd ɛfɛkt to yu dɔktɔ.
- I rili impɔtant fɔ tɛl yu dɔktɔ bɔt ɔl di ɔda mɛrɛsin dɛn, vaytamɛn dɛn, ɛn sɔpɔtmɛnt dɛn we yu de tek.
- Yu dɔktɔ we de mɛn kansa go no if dis tritmɛnt fayn fɔ yu afta dɛn dɔn du di tɛst.
Kansa, brɔst kansa, Orserdu, elacestrant, ɔmon tɛrapi, targeted tɛrapi, kansa mɛrɛsin
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt